



PATENT
ATTORNEY DOCKET NO. 44481-5017-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)

Vanitha RAMAKRISHNAN *et al.*)

Application No. 09/003,810)

Filed: January 7, 1998)

For: IMMUNOGLOBULIN POLYPEPTIDES)
TO HUMAN PDGF BETA RECEPTOR)

Group Art Unit: 1644

Examiner: P. Gambel

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants bring to the attention of the Examiner two (2) attached declarations of Dr. Neill Giese under 37 C.F.R. 1.132, submitted in parent Application No. 08/258,283, filed on June 10, 1994, (now U.S. Patent No. 5,817,310). Applicants also bring to the attention of the Examiner the attached declaration under 37 C.F.R. 1.131 of Vanitha Ramakrishnan, Maria Amelia Escobedo and Larry Fretto also submitted in parent Application No. 08/258,283, filed on June 10, 1994, (now U.S. Patent No. 5,817,310). Applicants respectively request that the attached declarations be made of record in the present Application.

Respectfully submitted,
MORGAN, LEWIS & BOCKIUS LLP

Michael S. Tuscan

Michael S. Tuscan
Registration No. 43,210

October 6, 1999
Customer No. 009629
MORGAN, LEWIS & BOCKIUS LLP
1800 M Street, NW
Washington, D.C. 20036
(202) 467-7000

RECEIVED
TECH CENTER 1500/2900
99 OCT - 7 AM 8:09

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231